PBL Interferonsource and Quansys Biosciences have entered an agreement to broaden Quansys' Q-Plex multiplex array offerings to enable the detection of interferons.
The agreement will grant PBL international and limited US rights to sell Quansys Q-Plex multiplex array kits and related products.
The combination of Quansys Q-Plex multiplex arrays with PBL's interferon reagents will allow researchers to simultaneously examine the relationship of multiple interferons and cytokines.
Using this assay platform, researchers in autoimmunity and infectious disease can address key questions in drug development and clinical research.
These include assessing cytokine profiles at various points throughout the course of disease, correlating alterations in cytokine profiles with patient responses to therapies, and determining off-target effects of drugs, all in an effort to predict clinical outcomes based on several biomarkers.
Robert Pestka, PBL Interferonsource president and chief executive officer, said: 'Our alliance with Quansys will allow both companies to better serve the global research community.
'It will significantly reduce the time, effort and costs researchers expend in conducting their work.
'This blend of cost-effective technology and interferon content should prove extremely beneficial to scientists developing the next generation of autoimmunity, viral and cancer therapeutics.' Quansys' Q-Plex technology platform includes multiplex arrays, custom array services, a chemiluminescent imaging system and powerful analysis software enabling researchers to run multiplex arrays in their lab on a cost-effective proprietary system.
PBL Interferonsource offers a selection of high-quality human and other mammal interferon-based products, including assay kits and reagents, IFN proteins, IFN monoclonal and polyclonal antibodies, and assay-development services.
